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Abstract
Insulin-degrading enzyme (IDE) is a ubiquitously expressed zinc-metalloprotease that degrades
several pathophysiologically significant extracellular substrates, including insulin and the amyloid β-
protein (Aβ), and accumulating evidence suggests that IDE dysfunction may be operative in both
type 2 diabetes mellitus and Alzheimer disease (AD). Although IDE is well known to be secreted
by a variety of cell types, the underlying trafficking pathway(s) remain poorly understood. To
address this topic, we investigated the effects of known inhibitors or stimulators of protein
secretion on the secretion of IDE from murine hepatocytes and HeLa cells. IDE secretion was
found to be unaffected by the classical secretion inhibitors brefeldin A (BFA), monensin, or
nocodazole, treatments that readily inhibited the secretion of α1-antitrypsin (AAT) overexpressed
in the same cells. Using a novel cell-based Aβ-degradation assay, we show further that IDE
secretion was similarly unaffected by multiple stimulators of protein secretion, including glyburide
and 3'-O-(4-benzoyl)benzoyl-ATP (Bz-ATP). The calcium ionophore, A23187, increased
extracellular IDE activity, but only under conditions that also elicited cytotoxicity. Our results
provide the first biochemical evidence that IDE export is not dependent upon the classical
secretion pathway, thereby identifying IDE as a novel member of the select class of
unconventionally secreted proteins. Further elucidation of the mechanisms underlying IDE
secretion, which would be facilitated by the assays described herein, promises to uncover
processes that might be defective in disease or manipulated for therapeutic benefit.
Results
Accumulating evidence from cell and animal modeling
studies and human molecular genetics implicates
impaired function of IDE in the pathogenesis of type 2
diabetes mellitus and Alzheimer disease (AD) [1-3]. IDE
is the prototypical member of an evolutionarily distinct
superfamily of zinc-metalloproteases possessing several
features that distinguish it from conventional metallopro-
teases, including an "inverted" zinc-binding motif
(HxxEH) [4] and an unusual tertiary structure [5-7].
Another distinguishing feature of IDE is its subcellular
localization: the vast majority of IDE is present in the
cytosol, with smaller amounts present in mitochondria,
peroxisomes, and endosomes [8]. A small fraction of
IDE–estimated to be 3% to 10% of the total–is also traf-
ficked to the extracellular space, and it is this pool which
interacts with known substrates of IDE, such as insulin
and Aβ [9]. Despite a large number of studies demonstrat-
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ing that IDE is secreted and/or associated with the cell sur-
face (e.g., [10-13]), little else is known about the
underlying export pathway(s).
In previous work, we showed that alternative translation
initiation of IDE mRNA at an initiation codon upstream
of the canonical one leads to the incorporation of a 41-
amino acid N-terminal sequence [14]. Bioinformatic anal-
ysis showed that this sequence was highly conserved (e.g.,
~80% identity between humans and pufferfish), implying
that it serves some important function, and some predic-
tion programs predicted it to be a bona fide signal
sequence [14]. Subsequent experimental analysis, how-
ever, showed unequivocally that this sequence instead
encodes a mitochondrial presequence, as demonstrated
by the localization of green fluorescent protein tagged
with this sequence, by electron microscopy, and by other
methods [14,15]. Moreover, overexpression of IDE iso-
forms encoding this sequence had no effect on the degra-
dation of extracellular substrates, in clear
contradistinction to isoforms translated beginning at the
canonical initiation codon [14,15].
Despite IDE's apparent lack of a classical signal peptide, it
is possible that the protein may nevertheless be exported
through the classical secretory pathway, whether medi-
ated by undefined postranslational modifications (e.g.,
proteolysis to reveal a cryptic signal sequence), by associ-
ation with heterologous classically secreted proteins, or by
other means dependent upon a functional classical secre-
tion pathway. To address this possibility, we co-trans-
fected immortalized murine hepatocytes with full-length,
unmodified cDNAs encoding human IDE and human α1-
antitrypsin (AAT), a widely studied classically secreted
protein [16]. Three days after transfection, cells were
washed then treated with each of 3 different inhibitors of
classical secretion: BFA (a blocker of ER-to-Golgi trans-
port), monensin (an ionophore of monovalent cations
that disrupts Golgi-dependent transport), and nocodazole
(an inhibitor of microtubule polymerization that inter-
feres with multiple forms of vesicular transport), or 0.1%
EtOH as a vehicle control. Cell lysates and conditioned
medium were collected, and the latter was concentrated
100-fold, then both were probed by western blotting for
IDE and AAT. As expected, each of the treatments led to a
significant decrease in the secretion of mature, ~62-kDa
AAT and a concomitant increase in intracellular AAT or
immature forms thereof (Fig. 1A, B). In striking contrast,
however, the levels of secreted IDE were unaffected by any
of these inhibitors of classical secretion (Fig. 1A, B). We
confirmed that these compounds produced no significant
cytotoxic effects at the concentrations tested, as judged by
quantification of lactate dehydrogenase (LDH) release
(data not shown).
To study effects on secreted IDE proteolytic activity per se,
we adapted our well-characterized fluorescence polariza-
tion-based Aβ degradation assay [17] for use in cells. To
that end, HeLa cells transfected with IDE cDNA or empty
vector were incubated for varying lengths of time with flu-
orescein-Aβ1–40-[Lys-LC-biotin] (FAβB) [17]. A time-
dependent increase in FAβB hydrolysis was observed that
was strongly increased in the IDE-overexpressing cells
(Fig. 2). In agreement with prior findings [12], FAβB
hydrolysis was inhibited nearly completely by insulin (20
μM), a competitive inhibitor of IDE. Collectively, these
results suggest that nearly all the Aβ-degrading activity
produced by these cells is attributable to IDE, making
FAβB degradation a reliable surrogate marker of extracel-
lular IDE activity.
We then used this experimental paradigm to evaluate the
effects of several inhibitors and activators of protein secre-
tion on endogenously secreted IDE activity. Consistent
with the results obtained above (Fig. 1), BFA, monensin
and nocodazole at several concentrations produced no
IDE secretion is unaffected by treatments that block the clas- sical secretion pathway Figure 1
IDE secretion is unaffected by treatments that block 
the classical secretion pathway. A, Representative west-
ern blots of concentrated conditioned medium (CM) and cell 
lysates from immortalized hepatocytes co-expressing IDE 
and AAT and treated with classical secretion inhibitors BFA 
(20 μM), monensin (Mon; 50 μM) or nocodazole (Noc; 3.3 
μM) or vehicle only (CTL). Note that the mature, secreted 
form of AAT migrates at 62 kDa. B, Quantification of west-
ern blots of secreted IDE and AAT. Data are mean ± SEM 
from 3 independent experiments.Molecular Neurodegeneration 2009, 4:4 http://www.molecularneurodegeneration.com/content/4/1/4
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significant effects on the secretion of IDE from HeLa cells
(Fig. 3A). We then tested several activators of conven-
tional and unconventional protein secretion, including
the ATP-binding cassette (ABC) transporter inhibitor gly-
buride, which is known to stimulate insulin secretion
from pancreatic beta cells; Bz-ATP, a known stimulator of
P2X7 receptors, which have been proposed to mediate the
unconventional secretion of IL-1β [18]; and the calcium
ionophore, A23187. No significant effect on IDE activity
was elicited by glyburide or Bz-ATP, but significant
enhancement was observed by treatment with A23187 for
2 h. Quantification of the effects of the different treat-
ments on LDH release in parallel experiments, however,
revealed that A23187 was significantly cytotoxic under the
conditions tested (Fig. 3B). Subsequent analysis showed
that treatment with A23187 for shorter durations (e.g. ≤
30 min) failed to produce significant effects on extracellu-
lar IDE activity or LDH release (not shown).
The primary goal of the present study was to establish
whether the secretion of IDE proceeds–directly or indi-
rectly–via the classical secretion pathway. Using two inde-
pendent methods, we show that the secretion of
catalytically active IDE is not affected by multiple inhibi-
tors of classical secretion. This result places IDE in the
emerging category of unconventionally secreted proteins,
which are characterized by the lack of a classical signal
peptide, the lack of posttranslational modifications spe-
cific for the ER and Golgi compartments, and resistance to
BFA and other inhibitors of Golgi-dependent export [19].
The list of proteins documented to be secreted by uncon-
ventional means is relatively small (i.e., approximately
20; see Ref. [19]), but it includes a number of medically
relevant proteins, such as fibroblast growth factor-1 and -
2 (FGF-2), interleukin-1α and IL-1β, thioredoxin,
galectins, and certain heat-shock and cytoskeletal proteins
[19,20]. Proteins associated specifically with neurodegen-
erative diseases have also been shown to be secreted by
unconventional means, including α-synuclein [21] and
prion protein [22].
The mechanisms underlying unconventional protein
secretion are largely mysterious, and only beginning to be
elucidated for just a subset of proteins. Nevertheless,
unconventional secretion can be usefully subdivided into
vesicular and nonvesicular pathways, with the former cat-
egory applying predominantly to integral-membrane pro-
A high-throughput-compatible fluorescence polarization- based assay for extracellular IDE activity detected by hydrol- ysis of FAβB Figure 2
A high-throughput-compatible fluorescence polariza-
tion-based assay for extracellular IDE activity 
detected by hydrolysis of FAβB. Time course of the 
hydrolysis of FAβB (0.5 μM) in HeLa cells transfected 2 days 
previously with human IDE cDNA (IDE), empty vector 
(Vect) or the latter treated with insulin (20 μM; Vect+Ins) to 
inhibit extracellular IDE activity and carried out in 384-well 
format. Data are mean ± SEM for 16 wells/condition.
Effects of inhibitors and stimulators of classical secretion on  extracellular IDE activity and cytotoxicity Figure 3
Effects of inhibitors and stimulators of classical secre-
tion on extracellular IDE activity and cytotoxicity. A, 
Extracellular IDE activity detected by FAβB hydrolysis in the 
absence (CTL) or presence of BFA (20 μM), monensin (Mon; 
50 μM), nocodazole (Noc; 3.3 μM), glyburide (250 μM), Bz-
ATP (100 μM), or A23187 (10 μM) in the presence of 1.8 
mM Ca2+ (A23187). Data are mean ± SEM for 16 wells per 
condition. *P < 0.01 by Student's T-test. B, LDH release 
induced by treatment with the aforementioned chemicals, 
unconditioned medium (DMEM), HeLa cell lysate (lysate) or 
recombinant LDH (LDH+). Data are mean ± SEM for 4 wells 
per condition in 96-well format. *P < 0.01 by Student's T-
test.Molecular Neurodegeneration 2009, 4:4 http://www.molecularneurodegeneration.com/content/4/1/4
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teins, and the latter applying to soluble proteins [19]. As a
soluble protein that lacks known ER/Golgi-specific post-
transalational modifications, IDE would appear to be
more likely to be secreted by nonvesicular means. Several
different nonvesicular pathways have been proposed to
underlie the export of different proteins, and our findings
shed light on which might apply to IDE export. IL-1β, for
example, has been proposed to be exported by activation
of the purinergic ionotropic P2X7 receptor, resulting in
release of the protein via microvesicle shedding [18]. The
present study appears to exclude the possibility that IDE is
secreted via the latter mechanism, since Bz-ATP, an activa-
tor of P2X7 receptors, was without effect (and HeLa cells
have been shown to express the P2X7 receptor abundantly
[23]). Secretion of FGF-2, on the other hand, has been
shown to proceed by direct translocation across the
plasma membrane, a process that is modulated by as-yet
undefined cytosolic factors [24]. Whether IDE secretion is
mediated by similar mechanisms as FGF-2 is currently
unknown, but would appear to be a question worthy of
future investigation. While the exact mechanisms underly-
ing IDE secretion remain to be elucidated, one exciting
aspect of unconventional protein transport is the possibil-
ity that protein-specific mechanisms may apply to the
secretion of individual proteins. If this is true for IDE, it
may be possible to selectively manipulate the secretion of
IDE, without affecting the secretion of unrelated proteins.
An ancillary, more practical outcome of the present study
is the demonstration that our well-characterized Aβ degra-
dation assay [17] is suitable for use in cells and, when cou-
pled with an LDH release assay, is capable of identifying
false-positive cytotoxic compounds. Significantly, in HeLa
cells and many other cell types (not shown), the vast
majority of extracellular Aβ degrading activity is inhibita-
ble by insulin, a highly selective IDE inhibitor, making
this assay useful for detecting extracellular IDE activity
directly. In the present study, the assay performed well at
multiple scales, including 384-well format. Given the rati-
ometric nature of the fluorescence polarization read-out
[17], this assay is well suited for high-throughput screen-
ing campaigns aimed at identifying chemical and genetic
modulators of IDE secretion, which may in turn help
uncover the detailed mechanisms underlying this poorly




BFA, monensin, nocodazole, glyburide, Bz-ATP, and
A23187 (Sigma) were prepared and stored according to
manufacturer's recommendations.
Cell Culture and Transfections
SV40-transformed wild-type murine hepatocytes were
plated in 24-well plates (2 × 105 cells/well), transfected
with appropriate cDNAs using TransIT LT1 according to
manufacturer's recommendations (Mirus) and main-
tained in Hepatocyte Medium (3H Biomedical AB) sup-
plemented with 20% fetal bovine serum. For experiments
with HeLa cells a "reverse transfection" procedure was car-
ried out in 384-well format (Mirus). Briefly, cDNA-Tran-
sIT LT1 complexes were prepared in Opti-MEM I low-
serum medium (Invitrogen), added to 384-well plates (20
μL/well), then HeLa cells suspended in DMEM/20% FBS
were added to the wells (20 μL/well; 10,000 cells/well).
Cells were grown under normal cell culture conditions
(37°C, 5% CO2 in a humidified chamber).
Collection of Secreted and Intracellular IDE and AAT for 
Biochemical Detection
Three days after transfection, immortalized murine hepa-
tocytes were washed 2 times in DMEM/0.1% bovine
serum albumin (BSA), then incubated with the latter
medium supplemented with appropriate chemicals or
0.1% EtOH as a vehicle control. Cells were pre-treated
with compounds for 30 min, washed, then cells were
allowed to condition the chemical-containing media for 2
h. Conditioned medium (250 uL/well, 6 wells/condition
for each experiment) was collected, cleared of cellular
debris by centrifugation, then concentrated 100-fold at
4°C using 2-mL YM-30 Microcon spin columns (Amicon)
according to manufacturer's recommendations. Cells
were washed twice with DMEM/0.1%BSA then lysed in
PBS supplemented with 0.1% Triton X100 and 1× Com-
plete Mini protease inhibitor cocktail (Roche) (30 uL/
well, 6 wells/condition). After incubation on ice for 30
min, the lysates were centrifuged at 10,000 g at 4°C for 10
min to pellet cell debris and unlysed cells.
Western Blot Analysis
Cell lysates and concentrated conditioned media were
subjected to SDS-PAGE under reducing conditions using
10% polyacrylamide tris-glycine mini gels (Invitrogen)
and transferred to nitrocellulose membranes as described
[25]. Membranes were blocked in 5% non-fat milk in tris-
buffered saline supplemented with 0.2% Tween-20 (TBS-
T), incubated for 1 h with antibodies against IDE (IDE-1;
1:1000; Ref. [13]; generous gift of Dennis Selkoe, Harvard
Medical School) or AAT (GAIT-80A; 1:1000; Immunology
Consultants Laboratory), washed with TBS-T, probed with
peroxidase-conjugated anti-rabbit IgG and anti-goat IgG
secondary antibodies, respectively (1:5000; Vector Labs),
and detected by enhanced chemoluminescence using
SuperSignal West Pico Substrate (Pierce). Western blots
were quantified using NIH Image 1.62 (NIH).Molecular Neurodegeneration 2009, 4:4 http://www.molecularneurodegeneration.com/content/4/1/4
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Cell-based FAβB Degradation Assay
HeLa cells plated in 384-well format (10,000 cells/well)
were washed twice in DMEM/0.1% BSA, then incubated at
37°C with the latter medium supplemented with FAβB
(0.5 μM; 40 μL/well). Reactions were terminated by addi-
tion of DMEM/0.1% BSA supplemented with avidin (2.5
μM) and 1,10 phenanthroline (5 mM; 10 μL/well). Fluo-
rescence polarization (λex = 485, λem = 535) was deter-
mined using a SpectraMax M5 microplate reader
(Molecular Devices). Controls included wells lacking cells
(0% hydrolysis), wells supplemented with 10 nM recom-
binant IDE (100% hydrolysis) or excess insulin (20 μM)
to establish IDE-dependent vs. IDE-independent hydroly-
sis. For experiments investigating the effects of chemicals
on FAβB degradation, in vitro tests were conducted to
guard against effects on the fluorescence polarization
read-out or on the activity of recombinant IDE.
Cytotoxicity assay
LDH release was quantified using the Cytotox 96 cytotox-
icity assay (Promega) according to manufacturer's recom-
mendations.
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